tiger accelerator logo square_edited.jpg

ManySmart

Pavilion:
RAPID-Health
Industry:
MedTech

About

Immunotherapy is the only breakthrough therapy in cancer treatment in recent years. One main requirement for successful cancer immunotherapy is to generate effective anti-tumor T-cell populations.


ManysmarT Therapeutics aims to deliver highly effective anti-tumor T-cell therapeutics by:


supplying abundant and high purity γ9δ2 T cells at an effector memory cell stage;

combining our ADCC (Antibody-Dependent Cell-mediated Cytotoxicity)-enhancing BiTE (Bispecific T cell Engager) to promote stronger interaction between therapeutic antibodies and the supplied/endogenous T cells and thus, result in a higher ADCC effect than that from using therapeutic antibodies alone;

combining γ9δ2 T cells with our own or commercial BiTEs to synergistically enhance their therapeutic effects;

enabling an easy switch to another therapeutic antibodies/targets to overcome the antigen loss issue commonly observed in advanced cancer;

generating neoantigen-specific T Cell Receptor (TCR)-redirected γ9δ2 T cells for cancer/infectious diseases treatment.



Contact Us

tiger accelerator logo square.png

Our Website:

Email Us:

Follow Us:

734383_in_linked_media_online_social_icon.png
734399_facebook_media_online_social_icon.png
734377_media_online_social_twitter_icon.png